VDI
SLS icon

Vaughan David Investments’s SELLAS Life Sciences SLS Stock Holding History

Vaughan David Investments’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-9
Closed -$8K – 167
2017
Q2 		$8K Hold
9
– – ﹤0.01% 168
2017
Q1 		$8K Buy
+9
New +$14.9K ﹤0.01% 165

Other funds holding SLS

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Vaughan David Investments's SLS Position: Q3 2017 in Review

Vaughan David Investments sold out of SELLAS Life Sciences (SLS) in Q3 2017, closing a stake of 9 shares — an estimated $8K sold.

Vaughan David Investments first reported a position in SLS in Q1 2017 and held it in 2 quarters. The position peaked at $8K in Q2 2017. 28 funds tracked by Wall St. Rank hold SLS as of Q3 2017.

  • Vaughan David Investments reported no remaining SELLAS Life Sciences position as of Q3 2017 after selling out during the quarter.
  • Vaughan David Investments sold 9 SELLAS Life Sciences shares in Q3 2017, an estimated $8K.
  • Vaughan David Investments first reported a position in SELLAS Life Sciences in Q1 2017 and held it in 2 quarters.
  • Vaughan David Investments's SELLAS Life Sciences position peaked at $8K in Q2 2017.
  • 28 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2017.

Based on Vaughan David Investments's 13F filing for Q3 2017, filed 8 Nov 2017.